[Wolff-Parkinson-White syndrome accompanying rapid conduction atrial fibrillation].
Mélon
P
P
Université de Liège.
Waleffe
A
A
Kulbertus
H
H
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D017115:Catheter Ablation; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004562:Electrocardiography; D005260:Female; D006329:Heart Conduction System / Q000601:surgery; D006801:Humans; D011342:Procainamide / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D014927:Wolff-Parkinson-White Syndrome / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery
D000889:Anti-Arrhythmia Agents; D011342:Procainamide
Syndrome de Wolff-Parkinson-White accompagné de fibrillation auriculaire à conduction rapide.